# FDA Regulation of Mesenchymal Exosomes: 351(a) vs 361

This document explores the critical distinctions between FDA 351(a) and 361 regulatory pathways as they pertain to mesenchymal stem cell (MSC) derived exosomes. We'll examine the key differences in approval processes, clinical trial requirements, manufacturing standards, and intended uses. This information is crucial for researchers, clinicians, and regulatory professionals working in regenerative medicine to understand the complex landscape of exosome regulation.


# Overview of FDA 351(a) Category

The FDA 351(a) category applies to biological products regulated as drugs under the Public Health Service Act. Mesenchymal stem cell (MSC) derived exosomes fall under this classification due to their intended use in treating diseases or conditions. This categorization has significant implications for the development and approval process of exosome-based therapies.

Products in the 351(a) category must undergo a rigorous approval process through the Biologics License Application (BLA). This process involves extensive clinical trials to demonstrate both safety and efficacy. The journey from initial development to market approval for 351(a) products is notoriously lengthy, complex, and expensive, often spanning 5-10 years and requiring investments in the hundreds of millions of dollars.

# Clinical Trials and Approval Process for 351(a) Products

1

## Preclinical Studies

Extensive laboratory and animal studies to assess safety and potential efficacy of the exosome product.

2

## IND Application

Submission of Investigational New Drug (IND) application to the FDA, detailing the product, manufacturing process, and clinical trial plans.

3

## Phase I Clinical Trials

Small-scale studies focusing on safety and dosage in healthy volunteers or patients.

4

## Phase II Clinical Trials

Larger studies to assess efficacy and further evaluate safety in patients with the target condition.

5

## Phase III Clinical Trials

Large-scale studies to confirm efficacy, monitor side effects, and compare to standard treatments.

6

## BLA Submission and Review

Compilation and submission of all data to the FDA for comprehensive review.

7

## FDA Approval

If approved, the product can be marketed for the specified indications.

# Current Status of Exosome Products under 351(a)

As of now, there are no FDA-approved exosome products under the 351(a) category. This absence of approved products underscores the rigorous nature of the approval process and the relative novelty of exosome-based therapies in the regulatory landscape. The lack of approved products also highlights the ongoing research and development efforts in this field, as companies and researchers work to navigate the complex regulatory requirements.

Despite the absence of approved products, there is significant interest and investment in exosome-based therapies. Many companies and research institutions are actively pursuing the development of MSC-derived exosome products, with several in various stages of clinical trials. This pipeline of potential therapies suggests that we may see FDA-approved exosome products in the future, pending successful completion of clinical trials and regulatory review.

# Overview of FDA 361 Category

The FDA 361 category applies to human cells, tissues, and cellular and tissue-based products (HCT/Ps) that meet specific criteria for minimal manipulation and homologous use. Unlike 351(a) products, those in the 361 category do not require pre-market approval from the FDA. However, they must comply with good tissue practice regulations to ensure safety and quality.

The 361 pathway is designed for products that are intended to perform the same basic function in the recipient as in the donor, with minimal processing. This category was created to facilitate the use of certain human tissues and cells in medical treatments without the need for the extensive approval process required for drugs or biological products.  Exosome products categorized as a 361 should not be used to treat medical conditions.  Practioners who ignore this regulation could have their medical license taken away and be charged with a felony.

# Why MSC-Derived Exosomes Don't Qualify for 361 Category

## More than Minimally Manipulated

The process of isolating and processing exosomes from MSCs significantly alters the original characteristics of the source tissue. This level of manipulation exceeds the "minimal manipulation" criterion for 361 products.

## Not for Homologous Use

Exosomes are typically used for purposes different from the original function of the source tissue. Their therapeutic applications often involve mechanisms distinct from the native functions of MSCs.

## Intended as Drug-like Therapies

MSC-derived exosomes are generally intended to treat diseases or conditions, which aligns more closely with the definition of drugs or biological products under 351(a) rather than the tissue-replacement focus of 361 products.

# Key Differences Between 351(a) and 361 Categories

| Aspect | 351(a) Category | 361 Category |
|---|---|---|
| Regulatory Pathway | Full FDA approval required | No pre-market approval needed |
| Clinical Trials | Extensive clinical trials necessary | Not required |
| Manufacturing Standards | Strict GMP standards | Good tissue practice regulations |
| Intended Use | Typically for treating diseases | For homologous use only and topical |
| Processing Level | Can involve significant manipulation | Minimal manipulation only |
| Review Process | Comprehensive FDA review | No formal FDA review for marketing |
| Legality | Legal to inject | For topical use only |
| Cost | $100M + | $0 |
| Time Investment | 5 to 10 years | 45 minute application |
| Requirements | Efficacy data<br>Pre-clinical studies Safety studies<br>3rd Party Lab Testing | None |



# Implications for Exosome Research and Development

The classification of MSC-derived exosomes under the 351(a) category has significant implications for researchers and companies developing exosome-based therapies. The rigorous approval process necessitates substantial investment in time and resources for preclinical studies, clinical trials, and regulatory compliance. This can pose challenges for smaller research institutions or startups with limited funding.

However, the 351(a) pathway also ensures a high standard of safety and efficacy for approved products. This rigorous vetting process can ultimately lead to more reliable and effective therapies, potentially increasing the likelihood of successful clinical outcomes and broader acceptance in the medical community. Researchers and companies must carefully consider these factors when planning their development strategies for exosome-based products.

# Regulatory Misconceptions and Compliance Challenges

There are instances where clinics or companies incorrectly claim their exosome products fall under the 361 category. This misclassification can lead to serious regulatory issues and potential risks to patient safety. The FDA has issued warnings to several entities marketing unapproved exosome products, emphasizing the importance of regulatory compliance.

Navigating the complex regulatory landscape presents significant challenges for researchers and companies. Staying informed about current FDA guidelines, seeking expert regulatory advice, and maintaining open communication with regulatory bodies are crucial steps in ensuring compliance. As the field of exosome research evolves, it's likely that regulatory frameworks will continue to adapt, requiring ongoing vigilance and flexibility from stakeholders in the industry.


# Future Outlook for Exosome Regulation

As research in exosome-based therapies continues to advance, it's possible that regulatory frameworks may evolve to better accommodate these novel treatments. The FDA has shown a willingness to adapt its approaches for emerging technologies, as evidenced by recent guidance documents specific to cell and gene therapies.

In the future, we might see the development of more tailored regulatory pathways for exosome-based products, potentially streamlining the approval process while maintaining high standards of safety and efficacy. Collaborative efforts between researchers, industry stakeholders, and regulatory bodies will be crucial in shaping a regulatory landscape that fosters innovation while protecting public health. As the field matures, the accumulation of safety and efficacy data may also inform more refined regulatory approaches specific to exosome-based therapies.